Rapid Development Framework™ solutions for cell, gene and RNA therapies
Accelerate your transition from idea to impact with confidence leveraging our standardized processes for RNA and viral vector development
With commercial approval rates as low as 10% for gene therapies and 17% for cell therapies at Phase 1, the stakes for early development are high.*
While many factors contribute to this considerable attrition, challenges associated with progressing innovative R&D processes to standardized and robust manufacturing methods are a driving force. Platform processes for cell, RNA and gene therapies have emerged as potential solutions to streamline development, but they may impose restrictive protocols that can stifle innovation and result in suboptimal outcomes.
As an alternative to this traditional approach, Thermo Fisher Scientific has developed the Rapid Development Framework™ solutions to accelerate the development and manufacturing of viral vectors and mRNA while remaining adaptable to the unique needs of each product. These frameworks enable control over your processes while leveraging standardized elements for improved efficiency and reliability—transforming the way therapies are brought to market.
Reduce development timelines and production costs
Promote consistency and quality across different batches and production sites
Streamline regulatory submission process
Learn more about our Rapid Development Framework™ solutions:
- Workflows for mRNA, saRNA, and LNP formulation including standardized analytics
- Supports early development through demo or tox batch production
- Uses standard chromatography based purification
- Can leverages pTRXi plasmid DNA backbone
- Applicable for transfection-based AAV and LV vectors produced within suspension cell culture and purified with chromatography
- Developed and tested through various clinical stages
- Scale up to 2,000 L (AAV)
- Leverages previously qualified platform analytics
- 9 months to GMP filled drug product
Featured helpful resources
View references